Youmanitarian
Youmanitarian 11 Jun 2021

Hasta la próxima

Testosterone & Testosterone Replacement Therapy (TRT) | Dr. Peter Attia & Dr. Andrew Huberma
24 May 2023
Testosterone & Testosterone Replacement Therapy (TRT) | Dr. Peter Attia & Dr. Andrew Huberma
uchetex · 16 vistas

PARP Inhibitors for Maintenance Therapy in Ovarian Cancer

18 vistas
TAKE ACTION
Donations would go to support charities for Cómo hacer y estilo

PARP, or poly-ADP ribose polymerase, inhibitors block repair of damaged DNA in tumor cells which increases cell death, especially in tumors with deficient repair mechanisms. One of the most recent important advances ovarian cancer treatment, PARP inhibitors have improved progression-free survival and are now being approved for first-line maintenance therapy in advanced stage disease. Several additional large-scale trials are underway with PARP inhibitors set to make great strides in improving outcomes in cancer therapy.

Mostrar más
More ways to take action
Explore ways that you can help bring a solution to this issue.

Hasta la próxima

Testosterone & Testosterone Replacement Therapy (TRT) | Dr. Peter Attia & Dr. Andrew Huberma
24 May 2023
Testosterone & Testosterone Replacement Therapy (TRT) | Dr. Peter Attia & Dr. Andrew Huberma
uchetex · 16 vistas